FGAM
IOVA icon

Financial Gravity Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Financial Gravity Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-33
Closed -$1K – 1549
2019
Q3 		$1K Hold
33
– – ﹤0.01% 1044
2019
Q2 		$1K Hold
33
– – ﹤0.01% 1065
2019
Q1 		$0 Buy
+33
New +$321 ﹤0.01% 1424

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Financial Gravity Asset Management's IOVA Position: Q4 2019 in Review

Financial Gravity Asset Management sold out of Iovance Biotherapeutics (IOVA) in Q4 2019, closing a stake of 33 shares — an estimated $1K sold.

Financial Gravity Asset Management first reported a position in IOVA in Q1 2019 and held it in 3 quarters. The position peaked at $1K in Q3 2019. 200 funds tracked by Wall St. Rank hold IOVA as of Q4 2019.

  • Financial Gravity Asset Management reported no remaining Iovance Biotherapeutics position as of Q4 2019 after selling out during the quarter.
  • Financial Gravity Asset Management sold 33 Iovance Biotherapeutics shares in Q4 2019, an estimated $1K.
  • Financial Gravity Asset Management first reported a position in Iovance Biotherapeutics in Q1 2019 and held it in 3 quarters.
  • Financial Gravity Asset Management's Iovance Biotherapeutics position peaked at $1K in Q3 2019.
  • 200 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2019.

Based on Financial Gravity Asset Management's 13F filing for Q4 2019, filed 28 Feb 2020.